Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Dec 12;93(12):1324-8.
doi: 10.1038/sj.bjc.6602872.

Management of febrile neutropenia in the United Kingdom: time for a national trial?

H Innes  1 , L Billingham, C Gaunt, N Steven, E Marshall
Affiliations

Management of febrile neutropenia in the United Kingdom: time for a national trial?

H Innes et al. Br J Cancer. .

Abstract

Recent advances in febrile neutropenia (FN) have highlighted the value of risk stratification and the evolving role of oral antibiotics with early hospital discharge in low-risk patients. The aim of this study was to survey whether these advances have been translated into routine clinical practice in the UK. Questionnaires were sent to cancer clinicians across the UK to determine clinicians' routine management of FN, including use of risk stratification, antibiotic regimen and criteria for hospital discharge. In all, 128 clinicians responded, representing 50 cancer departments (83%). Only 38% of respondents stratify patients according to risk and with substantial variation in the criteria defining 'low-risk'. Furthermore, only 22% of clinicians use oral antibiotics as first-line treatment in any patients with FN, but this was significantly greater among clinicians who do compared to those who do not stratify patients by risk, 51 vs 4% (P<0.0001). These findings suggest a slow and/or cautious introduction of newer strategies for the management of low-risk FN in the UK. However, 84% of respondents confirmed their willingness to participate in a trial of oral antibiotics combined with early discharge in low-risk FN.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of clinicians' antibiotic treatment of low-risk FN.
See this image and copyright information in PMC

References

    1. Bodey B, Groger AM, Bodey Jr B, Siegel SE, Kaiser HE (1997) Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493–498 - PubMed
    1. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Simple investigation in neutropenic individuals of the frequency of infection after chemotherapy +/− antibiotic in a number of tumours (SIGNIFICANT) trial group. N Engl J Med 353(10): 988–998 - PubMed
    1. Elting LS, Rubenstein EB, Rolston KV, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25: 247–259 - PubMed
    1. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341: 305–311 - PubMed
    1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730–751 - PubMed

MeSH terms

Substances